ALLR Hedge Fund & Institutional Holdings

At its annual meeting on June 26, 2026, Allarity Therapeutics shareholders voted on seven proposals. A quorum of 54.10% was present. Six proposals passed, including the election of a director, ratification of the auditor, an increase in authorized shares under the equity plan, advisory approval of executive compensation, and approval of a share issuance to Tumim Stone Capital. The only measure that failed was a proposal to limit officer liability under Delaware law. A proposal to adjourn the meeting if needed also passed.